Nov 15, 2022 / 02:10PM GMT
Stephen Willey - Stifel Financial Corp. - Analyst
Next session this morning is Compugen. Representing Compugen, we have Anat Cohen-Dayag, who is the Chief Executive Officer; Eran Ophir, who is the Chief Scientific Officer. Also in attendance, we have the new Chief Financial Officer, Alberto Sessa; and then from IR and Corporate Communications, we have Yvonne Naughton. Aran, before we get into any specific Q&A, you want to make any opening comments, or do you just want to?
Anat Cohen-Dayag - Compugen Ltd. - President & CEO
Yes. I'll just give a high-level overview about the company. We're a therapeutic-discovery and development company. We discover new drug targets, and we develop first-in-class drugs. Targeting these drug targets, focused in the field of cancer immunotherapy. We have four clinical-stage programs, four developed internally; and two are developed with -- by partners, AstraZeneca and Bayer.
And we also have an earlier stage pipeline addressing the various mechanisms of actions in the immune-suppressive tumor
Compugen Ltd at Stifel Healthcare Conference Transcript
Nov 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers